MX2020009738A - Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5. - Google Patents

Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5.

Info

Publication number
MX2020009738A
MX2020009738A MX2020009738A MX2020009738A MX2020009738A MX 2020009738 A MX2020009738 A MX 2020009738A MX 2020009738 A MX2020009738 A MX 2020009738A MX 2020009738 A MX2020009738 A MX 2020009738A MX 2020009738 A MX2020009738 A MX 2020009738A
Authority
MX
Mexico
Prior art keywords
derivatives
prmt5
prmt5 inhibitors
substituted imidazolidin
formula
Prior art date
Application number
MX2020009738A
Other languages
English (en)
Inventor
Dinesh Chikkanna
Sunil Kumar Panigrahi
Srinivasa Raju Sammeta
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of MX2020009738A publication Critical patent/MX2020009738A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

La presente invención se refiere a derivados de imidazolidin-2-ona sustituidos de la fórmula (I) o sales farmacéuticamente aceptables de los mismos. La presente invención proporciona además los métodos de preparación del compuesto de la fórmula (I) y su utilidad como inhibidor de PRMT5. Los compuestos son útiles como medicamentos en el tratamiento de afecciones y trastornos mediados por PRMT5, tales como cáncer, trastornos metabólicos, inflamación, enfermedades autoinmunes y hemoglobinopatías.
MX2020009738A 2018-03-22 2019-03-20 Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5. MX2020009738A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841010656 2018-03-22
PCT/IB2019/052252 WO2019180631A1 (en) 2018-03-22 2019-03-20 Substituted imidazolidin-2-one derivatives as prmt5 inhibitors

Publications (1)

Publication Number Publication Date
MX2020009738A true MX2020009738A (es) 2020-10-08

Family

ID=67986029

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009738A MX2020009738A (es) 2018-03-22 2019-03-20 Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5.

Country Status (15)

Country Link
US (1) US11542275B2 (es)
EP (1) EP3768671A4 (es)
JP (2) JP7254094B2 (es)
KR (1) KR20200135827A (es)
CN (1) CN112105609A (es)
AU (1) AU2019237329B2 (es)
BR (1) BR112020019111A2 (es)
CA (1) CA3092770A1 (es)
CU (1) CU24627B1 (es)
EA (1) EA202092253A1 (es)
IL (1) IL277518B2 (es)
MX (1) MX2020009738A (es)
PH (1) PH12020551494A1 (es)
SG (1) SG11202008526VA (es)
WO (1) WO2019180631A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768670A4 (en) * 2018-03-22 2021-11-24 Aurigene Discovery Technologies Limited IMIDAZOLIDIN-2-ON COMPOUNDS AS PRMT5 MODULATORS
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
KR20230094196A (ko) 2020-07-31 2023-06-27 탱고 테라퓨틱스, 인크. Mtap-결핍 및/또는 mta 축적 암의 치료에 유용한 피페리딘-1-일-n-피리딘-3-일-2-옥소아세트아마이드 유도체
CN115232147B (zh) * 2022-08-09 2023-10-13 南方科技大学 一种作为HIF-2α激动剂的杂环衍生物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69729583T2 (de) * 1996-04-17 2005-06-09 Bristol-Myers Squibb Pharma Co. N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
MY155570A (en) * 2009-06-26 2015-10-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
EP2702052B1 (en) * 2011-04-28 2017-10-18 Novartis AG 17alpha-hydroxylase/c17,20-lyase inhibitors
IN2012CH00067A (es) * 2012-01-06 2017-08-04
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2935242A2 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Methods of inhibiting prmt5
HUE040323T2 (hu) * 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
US9611257B2 (en) * 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014108820A1 (en) * 2013-01-08 2014-07-17 Aurigene Discovery Technologies Limited Substituted 2-pyrazinone derivatives as kinase inhibitors
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2017530940A (ja) 2014-08-04 2017-10-19 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
GB201604027D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
EP3266784A1 (en) 2016-06-08 2018-01-10 Pierre Fabre Medicament Protein arginine n-methyltransferases inhibitors and uses thereof

Also Published As

Publication number Publication date
US11542275B2 (en) 2023-01-03
KR20200135827A (ko) 2020-12-03
SG11202008526VA (en) 2020-10-29
EA202092253A1 (ru) 2021-01-14
CU20200067A7 (es) 2021-04-07
EP3768671A4 (en) 2021-11-24
JP2023082088A (ja) 2023-06-13
JP7254094B2 (ja) 2023-04-07
BR112020019111A2 (pt) 2021-01-12
CU24627B1 (es) 2022-11-07
IL277518B1 (en) 2023-09-01
AU2019237329B2 (en) 2024-03-28
CN112105609A (zh) 2020-12-18
EP3768671A1 (en) 2021-01-27
US20210002298A1 (en) 2021-01-07
PH12020551494A1 (en) 2021-09-01
IL277518A (en) 2020-11-30
AU2019237329A1 (en) 2020-10-01
JP2021518366A (ja) 2021-08-02
WO2019180631A1 (en) 2019-09-26
IL277518B2 (en) 2024-01-01
CA3092770A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12020551494A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
NZ726366A (en) Syk inhibitors
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-
EA202092600A1 (ru) Тетрациклические гетероарильные соединения